Immunotherapies for cancer and infectious diseases
Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biotechnology company focused on discovering and developing immune-targeted therapies for the treatment of cancers and infectious diseases.
Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biotechnology company focused on discovering and developing immune-targeted therapies for the treatment of cancers and infectious diseases.
Latest News
- March 20, 2019 - Transgene: A positive 2018, moving ahead with a strong portfolio (webcast)
- March 18, 2019 - Transgene secures a €20 Million Revolving Credit Facility with Natixis
- March 13, 2019 - Transgene – NEOVIVA project supporting the development of myvac™ awarded a €5.2 million grant from Bpifrance’s “Investments for the Future” programme
- March 5, 2019 - Transgene to start clinical development of lead myvacTM individualized immunotherapy, TG4050, in 2019, under its partnership with NEC
